Skip to main content
    E

    Enliven Therapeutics Inc. (ELVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $46.85
    -0.77 (-1.62%)

    Market Cap: $3.50B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Enliven Therapeutics Inc. (ELVN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Enliven Therapeutics (ELVN) has a market cap of $3.50B and an enterprise value of $3.35B. Its share count is up 25.59% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 4.33% below the market cap, as cash exceeds debt.

    Market Cap$3.50B
    Enterprise Value$3.35B
    Latest price (Nov 17, 2026)$46.85

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 17.85% in the quarter ended Sep 30, 2026 and grew 27.11% a year over 2 years.

    Shares Outstanding77.98M
    Shares Change (YoY)+25.59%
    Shares Change (QoQ)+17.85%
    Share Count Growth (2Y CAGR)+27.11%

    Price Statistics

    The stock is up 112.28% over 52 weeks and trades 1.96% above its 50-day average.

    Beta (1Y)1.12
    52-Week Change+112.28%
    1-Month Change+21.06%
    3-Month Change-21.11%
    6-Month Change+16.63%
    5-Year Change+207.29%
    Total Return (1Y)+112.28%
    Total Return (3Y CAGR)+65.14%
    Total Return (5Y CAGR)+28.47%
    Return vs SPY (1Y)+95.83%
    Max Drawdown (1Y)-38.97%
    Max Drawdown (3Y)-49.54%
    Sharpe Ratio (1Y)1.03
    Correlation with SPY (1Y)0.22
    50-Day Average$45.95
    200-Day Average$44.03
    52-Week Range$14.79 to $62.32
    RSI (14 Days)51.1
    Average Volume (20 Days)1.50M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 45.95x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio45.95x
    Quick Ratio45.95x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -12.94% and return on assets is -12.65% over the last 12 months.

    Return on Equity (ROE)-12.94%
    Return on Assets (ROA)-12.65%
    ROA (5Y Average)-35.10%
    ROIC (5Y Average)-20.58%

    Scores

    ELVN has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$46.00K
    Operating Income-$135.36M
    Pretax Income-$113.48M
    Net Income-$113.48M
    Reported EPS (TTM)-$1.71

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 97.74% of the $897.23M in total assets.

    Cash and Equivalents$151.67M
    Total Debt$0
    Net Cash$151.67M
    Net Cash Per Share$1.94
    Working Capital$875.28M
    Shareholder Equity$876.95M
    Book Value Per Share$11.25
    Total Assets$897.23M
    Total Liabilities$20.28M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $193.00K of capital spending, operating cash flow left -$66.41M of free cash flow.

    Operating Cash Flow-$66.22M
    Capital Expenditures$193.00K
    Free Cash Flow-$66.41M
    FCF Per Share-$0.91
    Depreciation and Amortization$1.98M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+16.47%
    Tangible Book Per Share Growth (2Y CAGR)+16.47%

    Revenue and profit by year

    Dividends and Yields

    ELVN does not pay a dividend. Its free cash flow yield is -1.82%.

    FCF Yield-1.82%
    Buyback Yield0.01%
    Shareholder Yield0.01%

    Stock Splits

    The last split was a 1-for-4 reverse split on Feb 24, 2023.

    Last Split DateFeb 24, 2023
    Split TypeReverse split
    Split Ratio1:4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ELVN

    What is ELVN's market cap?

    Enliven Therapeutics has a market cap of $3.50B. Its enterprise value, which adds debt and subtracts cash, is $3.35B.

    How many shares of ELVN are outstanding?

    Enliven Therapeutics has 77.98M shares outstanding. The count is up 25.59% from a year earlier.

    Does ELVN pay a dividend?

    No. Enliven Therapeutics does not pay a dividend.

    How much debt does ELVN have?

    Enliven Therapeutics has $0 of total debt and $151.67M of cash and equivalents, a net cash position of $151.67M.